Seabelife Biotech

We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.